Navigation Links
PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
Date:3/26/2013

MANSFIELD, Mass., March 26, 2013 /PRNewswire/ -- PrimeraDx, Inc., a molecular diagnostics company, today announced it has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics (NYSE: DGX), the world's leading diagnostics information services company.  The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.

Under the agreement, Quest Diagnostics has rights to use the PrimeraDx ICEPlex Platform to independently develop and use laboratory tests in early-phase biomarker and drug development studies and clinical trials with biotechnology, pharmaceutical and medical device clients of Quest Diagnostics Clinical Trials, a business of Quest Diagnostics. 

PrimeraDx will also have rights to develop and market in vitro diagnostic products, assuming FDA approvals for those targeted therapies.  In addition, Quest Diagnostics has rights to validate and offer clinical diagnostic information services, based in part on the assays created during drug development, as aids in making treatment decisions for those drugs that are successfully commercialized and FDA approved for clinical use.  

PrimeraDx launched the ICEPlex system in August 2011.  The system can simultaneously detect and quantify disparate target types, such as mRNA, miRNA, SNPs, DNA mutations, fusions and DNA methylation. Its ability to characterize complex molecular changes makes it well suited to research and development for diseases, such as cancer, that involve systemic or multiple molecular changes.  

The companies expect to direct their initial collaborations on cancer, although they may also explore opportunities in infectious diseases, gen
'/>"/>

SOURCE PrimeraDx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Trendlines Group Announces Co-development Agreement with Endo
2. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
3. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
4. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
5. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. QualityStar Presenting at Biomarkers & Diagnostics World Congress
11. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... , MONTREAL, Dec. 7 /PRNewswire/ - Enerkem Inc. ... been selected by the U.S. Department of Energy (DOE) to ... of its waste-to-biofuels facility to be located in Pontotoc, Mississippi. ... been selected in the larger demonstration scale project category of ...
... 7 ATS Medical, Inc. (Nasdaq: ATSI ), ... services today announced it has received CE Mark approval ... the European Union, indicating it is compliant with relevant ... The Enable valve is the first surgical aortic valve ...
... ... develop systems biology-driven therapeutics to include small molecules, chemotherapy and RNAi candidates and ... ... announced today that it has acquired Hermes Biosciences, Inc. a private biotechnology company ...
Cached Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
(Date:9/29/2014)... in Behavioral Brain Research provides novel insight ... result of chronic alcohol exposure that can lead to ... and research indicate that individuals with alcohol use disorders ... when people are actively drinking, when they are going ... "Sleep-wake disturbances can last for months, or even years, ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2
... Scientists have new information about the complex genetic ... of cognitive decline and dementia in the elderly. ... January issue of the American Journal of ... to look for genes associated with this devastating ...
... cancer cells for the whereabouts of an important tumor-suppressor, they ... broth instead of muscling its way out to the cells, ... of delinquency puzzled scientists for a long time until ... Medicine felt compelled to genetically grab the protein by the ...
... clinical trial suggests that long-term use of candesartan, a ... the symptoms of genetic heart disease. The related ... on left ventricular hypertrophy and function in non-obstructive hypertrophic ... issue of The Journal of Molecular Diagnostics . ...
Cached Biology News:Scientists make strides toward defining genetic signature of Alzheimer's disease 2Johns Hopkins scientists pull protein's tail to curtail cancer 2
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Feline IL-2, CF...
Recombinant Equine IL-4, CF...
Recombinant Rat Leptin, CF...
Biology Products: